Dry age-related macular degeneration

5 trials 1 recruiting MedDRA PT
5 Registered trials
1 Recruiting
5 Unique sponsors
3 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Phase III: 1 Phase II: 2 Phase I: 1 Phase I (Other): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Bolt Biotherapeutics Inc. Commercial
    ELAMIPRETIDE TRIHYDROCHLORIDE
    2024-511482-11-00 5 countries 2024 n=95
    Ended

Phase II

2 trials
  • Novartis Pharma AG Commercial
    FWY003 TOSILATE
    2025-523704-77-00 9 countries n=142
    Pending
  • ONL Therapeutics Inc. Commercial
    XELAFASLATIDE
    2024-513174-22-00 9 countries 2026 n=182
    Recruiting

Phase I

1 trial
  • PulseSight Therapeutics Commercial
    IMP not specified
    2024-519025-37-00 1 country 2025 n=12
    Ended

Phase I (Other)

1 trial
  • Bioinova a.s. Commercial
    IMP not specified
    2023-503573-38-00 1 country n=10
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
PulseSight Therapeutics Commercial 1 Phase I 0
Bioinova a.s. Commercial 1 Phase I (Other) 0
Novartis Pharma AG Commercial 1 Phase II 0
ONL Therapeutics Inc. Commercial 1 Phase II 1
Bolt Biotherapeutics Inc. Commercial 1 Phase III 0
New trials by year
2024
1
2025
1
2026
1
← All indication landscapes